SOHO 2021 | MRD-guided therapy for myeloma
Ola Landgren
• 23 Aug 2021
Ola Landgren, MD, PhD, of Sylvester Comprehensive Cancer Center, University of Miami, FL, discusses measurable residual disease (MRD)-guided therapy and it’s implications for the treatment of multiple myeloma. Dr Landgren explains that MRD negativity has been associated with both progression-free survival and overall survival and may be a viable tool to assess and accordingly alter the intensity of therapies. Although further research into the role of MRD-guided therapy is required, utilizing MRD negativity in this way seems to be a promising route for therapy optimization. This interview took place during the ninth annual meeting of the Society of Hematologic Oncology (SOHO 2021) congress.
